High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization.

This case report describes the first attempt to treat imminent ovarian hyperstimulation syndrome (OHSS) by using a gonadotrophin-releasing hormone (GnRH) antagonist. A 33 year old, normo-ovulatory woman undergoing in-vitro fertilization received daily subcutaneous injections of 150 IU of recombinant follicle-stimulating hormone (recFSH) from cycle day 2, together with GnRH antagonist (ganirelix) 0.125 mg from cycle day 7 onwards. On cycle day 10 the patient was found to have a serum oestradiol concentration of 16 500 pmol/l and, on ultrasound examination, four preovulatory (>16 mm) and nine intermediate sized (10-16 mm) follicles. RecFSH injections were discontinued, human chorionic gonadotrophin (HCG) withheld, whereas the ganirelix dose was increased to 2 mg/d. This regimen led to a rapid decrease in serum oestradiol concentrations and the decrease in ovarian size on ultrasound. Since GnRH antagonists will become clinically available for in-vitro fertilization programmes in the near future this suggested regimen might have a role in preventing severe OHSS.

[1]  P. Devroey,et al.  Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. , 1997, Fertility and sterility.

[2]  P. Devroey,et al.  Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix). , 1996, Human reproduction.

[3]  A. Schally,et al.  Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. , 1996, Endocrinology.

[4]  F. Ubaldi,et al.  Endocrinology: Subtle progesterone rise after the administration of the gonadotrophin-releasing hormone antagonist Cetrorelix in intracytoplasmic sperm injection cycles , 1996 .

[5]  S. Monroe,et al.  Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix). , 1995, Fertility and sterility.

[6]  M. Jakubowski,et al.  Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. , 1995, The Journal of clinical endocrinology and metabolism.

[7]  R. Fanchin,et al.  The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program. , 1994, Fertility and sterility.

[8]  D. Klingmüller,et al.  Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. , 1994, Human reproduction.

[9]  B. Charbonnel,et al.  Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH. , 1994, The Journal of clinical endocrinology and metabolism.

[10]  W. Hop,et al.  Endocrinology: Luteal function following ovulation induction in polycystic ovary syndrome patients using exogenous gonadotrophins in combination with a gonadotrophin-releasing hormone agonist , 1993 .

[11]  B. Lieberman,et al.  Is continuation of a gonadotrophin-releasing hormone agonist (GnRHa) necessary for women at risk of developing the ovarian hyperstimulation syndrome? , 1992, Human reproduction.

[12]  M. Sauer,et al.  The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. , 1991, American journal of obstetrics and gynecology.

[13]  M. Aboulghar,et al.  Modern management of ovarian hyperstimulation syndrome. , 1991, Human reproduction.

[14]  K. Gordon,et al.  A novel regimen of gonadotropin-releasing hormone (GnRH) antagonist plus pulsatile GnRH: controlled restoration of gonadotropin secretion and ovulation induction. , 1990, Fertility and sterility.

[15]  A. Pellicer,et al.  Steroidogenesis in vitro of human granulosa-luteal cells pretreated in vivo with gonadotropin-releasing hormone analogs. , 1990, Fertility and sterility.

[16]  D Jordan,et al.  GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. , 1989, Endocrinology.

[17]  J. Schenker,et al.  Ovarian Hyperstimulation Syndrome: A Current Survey , 1978 .

[18]  F. Ubaldi,et al.  Subtle progesterone rise after the administration of the gonadotrophin-releasing hormone antagonist cetrorelix in intracytoplasmic sperm injection cycles. , 1996, Human reproduction.

[19]  W. Hop,et al.  Luteal function following ovulation induction in polycystic ovary syndrome patients using exogenous gonadotrophins in combination with a gonadotrophin-releasing hormone agonist. , 1993, Human reproduction.

[20]  D. Klingmüller,et al.  Hormonal responses to the new potent GnRH antagonist Cetrorelix. , 1993, Acta endocrinologica.